Related Experiment Video
Updated: Mar 21, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Desirable Properties for 3rd Generation Cyclooxygenase-2 Inhibitors
Micky D Tortorella1, Yanmei Zhang, John Talley
1Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kai Yuan Avenue, Science Park, Guangzhou 510530, China. m.tortorella@gibh.org.
New coxibs aim to overcome the limitations of current drugs, such as poor solubility and cardiovascular risks. The goal is to develop safer and more effective COX-2 inhibitors for treating pain and inflammation.
Area of Science:
- Pharmacology
- Medicinal Chemistry
Background:
- Coxibs are potent cyclooxygenase-2 (COX-2) inhibitors widely used for pain and inflammation.
- Current coxibs present challenges including poor solubility, renal effects, and cardiovascular risks.
- Despite limitations, COX-2 inhibition remains a critical target for managing inflammatory diseases.
Purpose of the Study:
- To define the essential properties for next-generation coxibs.
- To guide the development of improved COX-2 inhibitors.
- To address the unmet medical need for safer and more effective anti-inflammatory drugs.
Main Methods:
- This study is a prospectus, outlining desired drug properties.
- It focuses on defining characteristics for third-generation coxibs.
- No experimental methods are detailed; it's a conceptual framework.
Main Results:
- The abstract does not present experimental results.
- It outlines the desired profile for future coxibs.
- Key desired properties include improved solubility and reduced cardiovascular and renal risks.
Conclusions:
- There is a significant need for improved coxibs.
- Future coxib development should prioritize enhanced safety and efficacy.
- Defining target properties is the first step toward new drug discovery.
More Related Videos
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cycloaddition Reactions: MO Requirements for Thermal Activation
Modified-Release Drug Delivery Systems: Influencing Factors
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: ɑ and β-Receptor Blockers